Fox Run Management L.L.C. decreased its stake in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 39.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,300 shares of the company’s stock after selling 4,700 shares during the quarter. Fox Run Management L.L.C.’s holdings in Aerie Pharmaceuticals were worth $355,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its stake in Aerie Pharmaceuticals by 11.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock valued at $140,000 after purchasing an additional 275 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after purchasing an additional 3,579 shares in the last quarter. Amalgamated Bank acquired a new position in Aerie Pharmaceuticals during the 2nd quarter valued at approximately $204,000. Palisade Capital Management LLC NJ acquired a new position in Aerie Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Finally, Gainplan LLC acquired a new position in Aerie Pharmaceuticals during the 2nd quarter valued at approximately $231,000. Institutional investors and hedge funds own 94.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/aerie-pharmaceuticals-inc-aeri-holdings-cut-by-fox-run-management-l-l-c/1675305.html.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02.

A number of research firms have recently weighed in on AERI. Mizuho reiterated a “buy” rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 25th. Guggenheim began coverage on shares of Aerie Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $80.00 price objective on the stock. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Canaccord Genuity reiterated a “positive” rating and issued a $73.00 price objective (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $76.00 price objective (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $69.71.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.